-
Atmo Biosciences receives US FDA clearance for ingestible gas-sensing capsule.
27 June 2025. Atmo Biosciences is delighted to announce that it has received US Food and Drug Administration (FDA) 510(k) clearance for the Atmo Gas Capsule System, paving the way for its first produc...
-
Atmo Biosciences Strengthens IP Portfolio with Assignment of Patents from RMIT University
April 15, 2025. Atmo Biosciences today announced the successful assignment of its foundational patent portfolio from RMIT University. Under this agreement, RMIT has transferred all patents and associa...
-
Atmo Biosciences announces publication of pivotal clinical study results supporting initial indication.
March 4, 2025. Today, Atmo Biosciences announced the publication of pivotal clinical study data in Clinical Gastroenterology and Hepatology. The study validates the Atmo Capsule for assessing whole an...
14 October 2024
Atmo awarded Stage 2 funding through ANDHealth+ program.
Atmo Biosciences is pleased to announce that it has been awarded funding through the ANDHealth+ Stage 2 Commercialization Program, aimed at helping five digital health companies scale their products nationally and internationally.
May 2, 2024
Atmo Gas Capsule used in Florida State University study assessing gastrointestinal impact of a fasting diet.
Atmo Biosciences’ ingestible gas-sensing capsule was used to assess the impact of an early-time restricted eating diet on gastrointestinal hydrogen production and gastrointestinal transit time.
April 9, 2024
Atmo Biosciences reaches primary endpoints in pivotal clinical study for initial indication.
Atmo Biosciences is delighted to report that it has successfully reached its primary endpoints in a pivotal clinical study to assess whole and regional gut transit time in subjects with suspected gastrointestinal motility disorders.
